AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Duodopa [folded into Other Neuroscience in Q1 2026] by Year
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M) ($M)
AbbVie Duodopa [folded into Other Neuroscience in Q1 2026]: $73M in FY2025, down 24.0% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73 | -24.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 96 | -1.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 97 | +2.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 95 | -6.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 102 | -1.0% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 103 | +6.2% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 97 | +21.2% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 80 | +31.1% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 61 | +64.9% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 37 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up duodopa [folded into Other Neuroscience in Q1 2026]
Cite this data
StockData. (2026). AbbVie Duodopa [folded into Other Neuroscience in Q1 2026] ($M), annual FY2016–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/duodopa-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.